MktsMarkets

Vor Biopharma Inc.
NASDAQ: VORKey statistics
VOR News
Stories mentioning VOR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 17,595 | 19,190 | 14,142 | 261,499 | 26,701 | 25,348 | 21,817 | 21,823 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 35,160 | 35,960 | 28,107 | 274,284 | 33,291 | 31,311 | 28,513 | 29,035 |
| Operating Income (Loss) | (35,160) | (35,960) | (28,107) | (274,284) | (33,291) | (31,311) | (28,513) | (29,035) |
| Interest Income | 3,935 | 2,795 | 1,731 | 537.00 | 805.00 | 599.00 | 954.00 | 1,196 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (219,585) | 1,722,858 | (812,684) | (1,573,669) | (32,486) | (30,712) | (27,559) | (27,839) |
| Earnings Per Share (Basic) | (5.11) | 174.52 | (121.63) | (12.56) | (5.21) | (8.94) | (8.05) | (0.41) |
| Earnings Per Share (Diluted) | (5.11) | 174.52 | (121.63) | (12.56) | (5.21) | (8.94) | (8.05) | (0.41) |
| Weighted Average Shares Outstanding (Basic) | 43,012 | 9,872 | 6,682 | 125,271 | 6,241 | 3,436 | 3,423 | 68,299 |
| Weighted Average Shares Outstanding (Diluted) | 43,012 | 9,872 | 6,682 | 125,271 | 6,241 | 3,436 | 3,423 | 68,299 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About VOR
Vor Biopharma Inc. (NASDAQ: VOR) is a stock listed on the Nasdaq Stock Market under the ticker symbol VOR. It last traded at $17.83 (Nov 18, 2026, 9:30 AM ET), down 1.9% on the day. That gives Vor Biopharma a market capitalisation of $1.2B and a price-to-earnings ratio of 0.9.
Over the past 52 weeks VOR has traded between $6.50 and $26.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $219.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$219.6M |
| Dec 31, 2025 | — | $1.7B |
| Sep 30, 2025 | — | -$812.7M |
| Jun 30, 2025 | — | -$1.6B |
From Vor Biopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…